Usability of an Application Device for Nabiximols Oromucosal Spray in Patients With Upper Limb Impaired Multiple Sclerosis

References

• Zwibel HL . Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv. Ther., 26(12), 1043–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Bensmail D , VermerschP. Epidemiology and clinical assessment of spasticity in multiple sclerosis. Rev. Neurol. (Paris), 168(Suppl. 3), S45–S50 (2012).
   PubMedGoogle Scholar
• Zettl UK , HenzeT, EssnerU, FlacheneckerP. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur. J. Health Econ., 15(9), 953–966 (2014).
   PubMed Web of Science ®Google Scholar
• Vermersch P . MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegener. Dis. Manag., 4(6), 407–415 (2014).
   PubMedGoogle Scholar
• Arroyo R , MassanaM, VilaC. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int. J. Neurosci., 123, 850–858 (2013).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK. Spasticity in patients with multiple sclerosis-clinical characteristics, treatment and quality of life. Acta Neurol. Scand., 129, 154–162 (2014).
   PubMed Web of Science ®Google Scholar
• Russo E , GuyGW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses, 66(2), 234–246 (2006).
   PubMed Web of Science ®Google Scholar
• Electronic medicines compendium (emc) Sativex® oromucosal spray. Summary of product characteristics (2018). www.medicines.org.uk/emc/product/602/smpc [ Sativex Oromucosal Spray – Summary of Product Characteristics (SmPC) – (emc) (medicines.org.uk).
   Google Scholar
• Collin C , DaviesP, MutibokoIK, RatcliffeS, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol., 14(3), 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Collin C , EhlerE, WaberzinekGet al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res., 32, 451–459 (2010).
   PubMed Web of Science ®Google Scholar
• Novotna A , MaresJ, RatcliffeSet al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol., 18, 1122–1131 (2011).
   PubMed Web of Science ®Google Scholar
• Markovà J , EssnerU, AkmazBet al. Sativex® as add-on therapy vs. further optimized first-line antispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int. J. Neurosci., 129, 119–128 (2019).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice – results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur. Neurol., 71, 271–279 (2014).
   PubMed Web of Science ®Google Scholar
• Flachenecker P , HenzeT, ZettlUK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur. Neurol., 72(1-2), 95–102 (2014).
   PubMed Web of Science ®Google Scholar
• Vermersch P , TrojanoM. Tetrahydrocannabinol:cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. Eur. Neurol., 76, 216–226 (2016).
   PubMed Web of Science ®Google Scholar
• Patti F , MessinaS, SolaroCet al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J. Neurol. Neurosurg. Psychiatry, 87(9), 944–951 (2016).
   PubMed Web of Science ®Google Scholar
• Ferrè L , NuaraA, PavanGet al. Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol. Sci., 37(2), 235–242 (2016).
   PubMed Web of Science ®Google Scholar
• Prieto González JM , Vila SilvánC. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries and case reports. Exp. Rev. Neurother., 21(5), 547–558 (2021).
   PubMed Web of Science ®Google Scholar
• Vachová M , NovotnáA, MaresJet al. A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J. Mult. Scler., 1, 122 (2014).
   Google Scholar
• Alessandria G , MeliR, InfanteMT, VestitoL, CapelloE, BandiniF. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: a pilot study. Clin. Neurol. Neurosurg., 196, 105990 (2020).
   PubMed Web of Science ®Google Scholar
• Freidel M , Tiel-WilckK, SchreiberH, PrechtlA, EssnerU, LangM. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability. Acta Neurol. Scand., 131(1), 9–16 (2015).
   PubMed Web of Science ®Google Scholar
• European Commission . DG health and consumer. Directorate B, unit B2 “cosmetics and medical devices”. Medical devices: guidance document – classification of medical devices. Guidelines relating to the application of the council directive 93/42/EEC on medical devices. (MEDDEV 2. 4/1 rev). (2010). https://pdf4pro.com/amp/view/medical-devices-guidance-document-2bddb.html
   Google Scholar
• Montero-Escribano P , Vila SilvánC. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing. Expert Rev. Med. Devices, 16(9), 835–840 (2019).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology, 33(11), 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Solaro C , GrangeE, DiGiovanni Ret al. Nine Hole Peg Test asymmetry in refining upper limb assessment in multiple sclerosis. Mult. Scler. Relat. Disord., 45, 102422 (2020).
   PubMed Web of Science ®Google Scholar
• Otero-Romero S , Sastre-GarrigaJ, ComiGet al. Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult. Scler., 22(11), 1386–1396 (2016).
   PubMed Web of Science ®Google Scholar
• Lucas CJ , GalettisP, SchneiderJ. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol., 84(11), 2477–2482 (2018).
   PubMed Web of Science ®Google Scholar